The combination of hypolipidemic drugs is considered an effective approach in the treatment of hyperlipidemias. We selected the combination of polyunsaturated phospholipids (EPL) and Lovastatin (HMG CoA reductase inhibitor) for investigation in a prospective, randomized, double-blind, placebo-controlled parallel group trial. It has been conclusively shown that the combined therapy of EPL with a low-dose of Lovastatin results in an effective decrease of LDL-cholesterol levels in an 8 weeks treatment course. The requested LDL-cholesterol level (130 mg/dl) was observed in more cases under the lower Lovastatin dose (20 mg per day) plus EPL in comparison with Lovastatin alone. EPL prolongs the achieved hypolipidemic effect of the combined therapy and reduces the sharp increase of plasma lipid levels during interruption of the Lovastatin treatment. Furthermore, EPL effectively reduces the alanine aminotransferase activity as well as spontaneous and induced platelet aggregation which were increased after long-term Lovastatin therapy. The combination of EPL with Lovastatin markedly reduces the costs of the long-term treatment. It has been shown in this double-blind, placebo-controlled trial that a combined therapy of polynsaturated phospholipids (EPL) with a low-dose of Lovastatin effectively decreases LDL-cholesterol levels in an 8 weeks treatment course. The combination markedly the costs of the long-term treatment.